ADMA Biologics (ADMA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.02), Fidelity Earnings reports. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $5.39 million.

NASDAQ:ADMA traded down $0.48 during midday trading on Friday, reaching $5.26. 175,312 shares of the stock traded hands, compared to its average volume of 228,164. ADMA Biologics has a 12-month low of $2.10 and a 12-month high of $6.96. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $254.46 million, a price-to-earnings ratio of -2.75 and a beta of 2.28.

Several equities research analysts have recently weighed in on ADMA shares. Raymond James reaffirmed a “buy” rating and issued a $10.00 price target (down previously from $11.00) on shares of ADMA Biologics in a research report on Friday, October 12th. Oppenheimer set a $13.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Wednesday, October 17th. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price target on shares of ADMA Biologics in a research report on Wednesday, October 17th. Finally, Chardan Capital started coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $11.58.

An institutional investor recently raised its position in ADMA Biologics stock. Bank of New York Mellon Corp boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 188.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,828 shares of the biotechnology company’s stock after acquiring an additional 35,791 shares during the period. Bank of New York Mellon Corp owned 0.12% of ADMA Biologics worth $247,000 as of its most recent filing with the Securities & Exchange Commission. 55.07% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/11/09/adma-biologics-adma-releases-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: Dollar Cost Averaging

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply